A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer|Melanoma|Triple Negative Breast Cancer|Colorectal Cancer
Interventions: DRUG: NM1F Injection|DRUG: Pembrolizumab injection
Sponsor: Hefei TG ImmunoPharma Co., Ltd.